Company Profile
Day One Biopharmaceuticals Stock Price, News & Analysis
- Ticker:
- DAWN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
21.53 USD (+0.19%)
Close
Last updated: April 22, 2026
2.22B USD
Market cap
Why the stock is moving
Current closing-price context is not available for DAWN.
Company overview
Pediatric and Rare Oncology
Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types.
OJEMDA
OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an activating RAF alteration. It provides Day One’s commercial foundation and is being studied in the frontline setting.
FIREFLY Program
FIREFLY-1 supported approval and continues to provide long-term durability data. FIREFLY-2 is a pivotal Phase 3 trial evaluating OJEMDA in newly diagnosed pediatric low-grade glioma.
Emi-Le
Emi-Le is a B7-H4-directed antibody-drug conjugate acquired with Mersana Therapeutics. It is in Phase 1 development for adenoid cystic carcinoma and broadens Day One into rare adult cancers.
DAY301
DAY301 is a PTK7-targeted antibody-drug conjugate in Phase 1a dose escalation. The program adds a second ADC mechanism and another opportunity beyond the OJEMDA franchise.
Future catalysts
Completion of enrollment in the Phase 3 FIREFLY-2 trial expected in the first half of 2026.
Updated Phase 1 Emi-Le data expected in mid-2026.
Initial Phase 1a DAY301 data and program update expected in the second half of 2026.
Recent news
- 01
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Source: Day One Biopharmaceuticals
- 02
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Source: Day One Biopharmaceuticals
- 03
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
Source: Day One Biopharmaceuticals
- 04
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Source: Day One Biopharmaceuticals
- 05
Day One Completes Acquisition of Mersana Therapeutics
Source: Day One Biopharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Day One Biopharmaceuticals (DAWN)?
Day One Biopharmaceuticals (DAWN) most recently closed at 21.53 USD, a +0.19% move versus the previous session.
What is the market cap of Day One Biopharmaceuticals (DAWN)?
Day One Biopharmaceuticals currently has a market capitalization of 2.22B USD on BioPharmSignal.
What does Day One Biopharmaceuticals do?
Pediatric and Rare Oncology Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types. OJEMDA OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an activating RAF...
On which exchange is DAWN stock listed?
Day One Biopharmaceuticals (DAWN) is associated with NASDAQ, United States, Biopharma.
What is FIREFLY-1?
FIREFLY Program FIREFLY-1 supported approval and continues to provide long-term durability data.
Which conditions is Day One Biopharmaceuticals targeting with FIREFLY-1?
Day One Biopharmaceuticals is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Day One Biopharmaceuticals describe recent progress with FIREFLY-1?
Completion of enrollment in the Phase 3 FIREFLY-2 trial expected in the first half of 2026. Updated Phase 1 Emi-Le data expected in mid-2026. Initial Phase 1a DAY301 data and program update expected in the second half of 2026.
What is FIREFLY-2?
FIREFLY-2 is a pivotal Phase 3 trial evaluating OJEMDA in newly diagnosed pediatric low-grade glioma.